Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. Co.'s clinical-stage pipeline include: AVTX-002, which is a fully human monoclonal antibody, directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator, a receptor expressed by T lymphocytes) being developed for the treatment of non-eosinophilic asthma; AVTX-008, which is a fully human B and T Lymphocyte Attenuator agonist fusion protein; and AVTX-803, which is a fucose replacement for leukocyte adhesion deficiency type II. The AVTX stock yearly return is shown above.
The yearly return on the AVTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AVTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|